American Society of Hematology 2020 guidelines for management of venous #thromboembolism: treatment of deep vein #thrombosis and pulmonary #embolism

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in ∼1 to 2 individuals per 1000 each year, corresponding to ∼300 000 to 600 000 events in the United States annually.. ..Strong recommendations include the use of thrombolytic therapy for patients with PE and hemodynamic compromise, use of an international normalized ratio (INR) range of 2.0 to 3.0 over a lower INR … Continue reading American Society of Hematology 2020 guidelines for management of venous #thromboembolism: treatment of deep vein #thrombosis and pulmonary #embolism

Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial

Patients with unprovoked (i.e., without the presence of apparent transient risk factors such as recent surgery) venous thromboembolism (VTE) are at risk of recurrence if anticoagulants are stopped after 3–6 months, yet their risk remains heterogeneous. Thus, prolonging anticoagulant treatment should be considered in high-risk patients, whereas stopping is likely preferred in those with a low predicted risk. The Vienna Prediction Model (VPM) could aid … Continue reading Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial

Post-Discharge Prophylaxis With #Rivaroxaban Reduces Fatal and Major #Thromboembolic Events in Medically Ill Patients

Hospitalized acutely ill medical patients are at risk for fatal and major thromboembolic events. Whether use of extended-duration primary thromboprophylaxis can prevent such events is unknown.. ..Medically ill patients with a baseline creatinine clearance ≥50 ml/min were randomized in a double-blind fashion to rivaroxaban 10 mg or placebo daily at hospital discharge for 45 days. Exploratory efficacy analyses were performed with the intent-to-treat population including … Continue reading Post-Discharge Prophylaxis With #Rivaroxaban Reduces Fatal and Major #Thromboembolic Events in Medically Ill Patients

Clinical Effectiveness and Safety of #Aspirin for Venous #Thromboembolism Prophylaxis After Total Hip and Knee Replacement

Patients undergoing total hip replacement (THR) and total knee replacement (TKR) receive venous thromboembolism (VTE) pharmacoprophylaxis. It is unclear which anticoagulant is preferable. Observational data suggest aspirin provides effective VTE prophylaxis.. ..The RR of VTE after THR and TKR was 1.12 (95% CI, 0.78-1.62) for aspirin compared with other anticoagulants. Comparable findings were observed for deep vein thrombosis (DVT) (RR, 1.04; 95% CI, 0.72-1.51) and … Continue reading Clinical Effectiveness and Safety of #Aspirin for Venous #Thromboembolism Prophylaxis After Total Hip and Knee Replacement

#Hemoglobin concentration and risk of arterial and venous #thrombosis in 1.5 million Swedish and Danish blood donors

..The risk of myocardial infarction and ischemic stroke increased with higher hemoglobin concentration in both men and women. The HRs for myocardial infarction and ischemic stroke in men with hemoglobin concentration ≥ 17.5 g/dL were 3.52 (95% confidence interval [CI], 2.85–4.36) and 2.36 (95% CI, 1.63–3.43), respectively, compared to the reference group. The corresponding HRs for women with hemoglobin concentration ≥ 16.0 g/dL were 3.22 (2.12–4.89) and 2.35 (1.37–4.02) for myocardial … Continue reading #Hemoglobin concentration and risk of arterial and venous #thrombosis in 1.5 million Swedish and Danish blood donors

Safety and efficacy of high-dose unfractionated #heparin versus high-dose enoxaparin for venous #thromboembolism prevention in morbidly obese hospitalized patients

..A single-center retrospective observational study was conducted in morbidly obese (body mass index ≥ 40 kg/m2) hospitalized patients who received either high-fixed dose enoxaparin (40 mg every 12 hours) or unfractionated heparin (7,500 units every 8 hours) for venous thromboembolism prophylaxis. ..In the 305 patients included (n=190 unfractionated heparin, n=115 enoxaparin), the incidence of major bleeding was significantly higher in the unfractionated heparin group (OR … Continue reading Safety and efficacy of high-dose unfractionated #heparin versus high-dose enoxaparin for venous #thromboembolism prevention in morbidly obese hospitalized patients

#THROMBOEMBOLIC RISK IN MEDICAL PATIENT: AN EXTENSIVE REVIEW AND FUTURE PERSPECTIVES

..Many studies have proven relevant reduction of fatal pulmonary embolism due to improved medical practice aimed to provide proper thromboembolic prophylactic therapy. RESULTS: Despite scientific efforts in clinical prevention, influence of some patients demographic variables are often underestimated (i.e. older age..) and real burden of absolute venous thromboembolic risk and thromboprophylactic efficacy remain unclear. Moreover, establishment and development of Emergency and Acute Care Departments select … Continue reading #THROMBOEMBOLIC RISK IN MEDICAL PATIENT: AN EXTENSIVE REVIEW AND FUTURE PERSPECTIVES

#Rivaroxaban Versus Vitamin K Antagonist in #Antiphospholipid Syndrome: A Randomized Noninferiority Trial

After 3 years of follow-up, recurrent thrombosis occurred in 11 patients (11.6%) in the rivaroxaban group and 6 (6.3%) in the VKA group (RR in the rivaroxaban group, 1.83 [95% CI, 0.71 to 4.76]). Stroke occurred more commonly in patients receiving rivaroxaban (9 events) than in those receiving VKAs (0 events) (corrected RR, 19.00 [CI, 1.12 to 321.9]). Major bleeding occurred in 6 patients (6.3%) … Continue reading #Rivaroxaban Versus Vitamin K Antagonist in #Antiphospholipid Syndrome: A Randomized Noninferiority Trial